Atlas Brown’s Teva Pharmaceuticals TEVA Stock Holding History

Atlas Brown’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-7,485	Closed	-$293K	–	92
2013 Q2	$293K	Buy	+7,485	New	+$291K	0.06%	107

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Atlas Brown's TEVA Position: Q3 2013 in Review

Atlas Brown sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 7,485 shares — an estimated $293K sold.

Atlas Brown first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $293K in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

Atlas Brown reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
Atlas Brown sold 7,485 Teva Pharmaceuticals shares in Q3 2013, an estimated $293K.
Atlas Brown first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
Atlas Brown's Teva Pharmaceuticals position peaked at $293K in Q2 2013.
705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Atlas Brown's 13F filing for Q3 2013, filed 31 Oct 2013.